Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.
Bottom Line: Regular and isophane insulin (NPH), glibenclamide, metformin and gliclazide were the DU-90 drugs in 2012.Metformin, glibenclamide and regular/NPH insulin combination therapy were affordable throughout the study period (∼0.4, ∼0.1, ∼0.3 of minimum daily wage, respectively).While the affordability of novel insulin preparations improved over time, they were still unaffordable in 2012.
Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.Show MeSH
Related in: MedlinePlus
Mentions: Benchmarking with OECD countries showed that Iran had a low A10 utilisation in 2011 (figure 3). The prevalence of diabetes in Australia, Finland, Germany, Spain and Estonia were similar to Iran in 2011 (8–10%). The utilisation of A10 medicines increased in all of these countries from 2000 to 2011 but the magnitude of growth was highest in Iran (430.7%). Nevertheless, the annual per capita A10 utilisation in Iran was consistently and substantially lower than those five countries during the benchmarking period (figure 4).
Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.